window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 9, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

glass vials

  • Biotech & Pharma Business,Manufacturing & Supply Chain

    SGD Pharma reports emissions reduction and sustainable packaging progress

    SGD Pharma has reported a 27% reduction in Scope 1 [...]

    July 9, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week

    Interview with Carol Grassi Mircich, chief commercial marketing and innovation [...]

    May 5, 2026
  • Drug Delivery & Formulation,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    SGD Pharma leads pharma packaging innovation and decarbonisation at Pharmapack Europe 2026

    SGD Pharma, a global producer of pharmaceutical glass primary packaging, [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Healome raises £2M to advance eye-drop technology for ocular surface diseases
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development
  • Xeltis completes first commercial implant of aXess haemodialysis device
    Categories: Clinical & Regulatory, Medical devices
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top